AU2020206672B2 - Polypeptides comprising modified IL-2 polypeptides and uses thereof - Google Patents
Polypeptides comprising modified IL-2 polypeptides and uses thereofInfo
- Publication number
- AU2020206672B2 AU2020206672B2 AU2020206672A AU2020206672A AU2020206672B2 AU 2020206672 B2 AU2020206672 B2 AU 2020206672B2 AU 2020206672 A AU2020206672 A AU 2020206672A AU 2020206672 A AU2020206672 A AU 2020206672A AU 2020206672 B2 AU2020206672 B2 AU 2020206672B2
- Authority
- AU
- Australia
- Prior art keywords
- cancer
- antigen binding
- binding domain
- polypeptide
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2815—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2025283608A AU2025283608A1 (en) | 2019-01-07 | 2025-12-19 | Polypeptides comprising modified IL-2 polypeptides and uses thereof |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962789075P | 2019-01-07 | 2019-01-07 | |
| US62/789,075 | 2019-01-07 | ||
| PCT/US2020/012296 WO2020146221A1 (en) | 2019-01-07 | 2020-01-06 | Polypeptides comprising modified il-2 polypeptides and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2025283608A Division AU2025283608A1 (en) | 2019-01-07 | 2025-12-19 | Polypeptides comprising modified IL-2 polypeptides and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2020206672A1 AU2020206672A1 (en) | 2021-07-15 |
| AU2020206672B2 true AU2020206672B2 (en) | 2025-10-02 |
Family
ID=69374426
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020206672A Active AU2020206672B2 (en) | 2019-01-07 | 2020-01-06 | Polypeptides comprising modified IL-2 polypeptides and uses thereof |
| AU2025283608A Pending AU2025283608A1 (en) | 2019-01-07 | 2025-12-19 | Polypeptides comprising modified IL-2 polypeptides and uses thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2025283608A Pending AU2025283608A1 (en) | 2019-01-07 | 2025-12-19 | Polypeptides comprising modified IL-2 polypeptides and uses thereof |
Country Status (15)
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101520534B1 (ko) | 2012-05-07 | 2015-05-21 | 고려대학교 산학협력단 | 말초혈액단핵구 유래 자연 살해세포의 유도 및 증식 방법 |
| IL321812A (en) | 2017-08-03 | 2025-08-01 | Synthorx Inc | Cytokine complexes for the treatment of autoimmune diseases |
| CN115710576A (zh) | 2018-02-01 | 2023-02-24 | Nkmax有限公司 | 产生天然杀伤细胞的方法和用于治疗癌症的组合物 |
| TW202031284A (zh) | 2018-11-08 | 2020-09-01 | 美商新索思股份有限公司 | 介白素10結合物及其用途 |
| MA54952A (fr) | 2019-02-06 | 2022-05-11 | Synthorx Inc | Conjugués d'il-2 et méthodes d'utilisation de ceux-ci |
| CA3148135A1 (en) | 2019-08-23 | 2021-03-04 | Carolina E. CAFFARO | Il-15 conjugates and uses thereof |
| WO2021050554A1 (en) | 2019-09-10 | 2021-03-18 | Synthorx, Inc. | Il-2 conjugates and methods of use to treat autoimmune diseases |
| CN115916831A (zh) * | 2020-06-30 | 2023-04-04 | Gi 医诺微新 | 包含抗lag-3抗体和il-2的融合蛋白及其用途 |
| EP4175979A2 (en) * | 2020-07-02 | 2023-05-10 | Inhibrx, Inc. | Polypeptides comprising modified il-2 polypeptides and uses thereof |
| KR20230112632A (ko) | 2020-10-23 | 2023-07-27 | 애셔 바이오테라퓨틱스, 인크. | 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합 |
| WO2022099090A1 (en) * | 2020-11-06 | 2022-05-12 | Xencor, Inc. | Heterodimeric antibodies that bind tgfbrii |
| EP4251187A4 (en) | 2020-11-25 | 2025-09-10 | Xilio Dev Inc | TUMOR-SPECIFIC CLASSIBLE LINKERS |
| JP2023553216A (ja) * | 2020-12-09 | 2023-12-20 | アシャ バイオセラピューティクス,インク. | 遺伝子操作細胞療法のための標的化サイトカイン構築物 |
| CN112979782B (zh) * | 2021-03-08 | 2023-07-18 | 深圳市乐土生物医药有限公司 | 一种多肽及其用途 |
| CA3213751A1 (en) * | 2021-03-31 | 2022-10-06 | Ziyang Zhong | Fusion proteins, pharmaceutical compositions, and therapeutic applications |
| TW202321283A (zh) * | 2021-07-20 | 2023-06-01 | 美商英伊布里克斯公司 | Cd8結合多肽及其用途 |
| TW202309102A (zh) * | 2021-07-20 | 2023-03-01 | 美商英伊布里克斯公司 | 靶向cd8之經修飾il-2多肽及其用途 |
| TW202319397A (zh) * | 2021-08-30 | 2023-05-16 | 美商英伊布里克斯公司 | NKp46結合多肽及其用途 |
| TW202328171A (zh) * | 2021-08-30 | 2023-07-16 | 美商英伊布里克斯公司 | 靶向NKp46之經修飾之IL-2多肽及其用途 |
| JP2024536840A (ja) * | 2021-09-26 | 2024-10-08 | ウーシー バイオロジクス アイルランド リミテッド | Il-2バリアント及びその融合タンパク質 |
| TW202334193A (zh) * | 2022-01-05 | 2023-09-01 | 美商英伊布里克斯公司 | 靶向γδ T細胞之經修飾IL-2多肽及其用途 |
| WO2024026449A2 (en) * | 2022-07-28 | 2024-02-01 | Proviva Therapeutics (Hong Kong) Limited | Il-2 procytokine antibody fusion proteins |
| WO2025151752A1 (en) | 2024-01-10 | 2025-07-17 | Xilio Development, Inc. | Masked il-2 cytokines and methods of use thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005086798A2 (en) * | 2004-03-05 | 2005-09-22 | Chiron Corporation | Improved interleukin-2 muteins |
| WO2016164937A2 (en) * | 2015-04-10 | 2016-10-13 | Amgen Inc. | Interleukin-2 muteins for the expansion of t-regulatory cells |
| WO2018170168A1 (en) * | 2017-03-15 | 2018-09-20 | Cue Biopharma, Inc. | Methods for modulating an immune response |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| WO1999029888A1 (en) | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
| EP1454138B1 (en) * | 2001-12-04 | 2012-01-18 | Merck Patent GmbH | Immunocytokines with modulated selectivity |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| DK1678314T3 (da) | 2003-10-22 | 2012-12-03 | Keck Graduate Inst | Fremgangsmåde til syntetisering af heteromultimere polypeptider i gær ved anvendelse af en haploid parringsstrategi |
| CN1930300A (zh) * | 2004-03-05 | 2007-03-14 | 希龙公司 | 预测患者治疗药物耐受性的体外试验系统 |
| CN1961003B (zh) | 2004-03-31 | 2013-03-27 | 健泰科生物技术公司 | 人源化抗TGF-β抗体 |
| CN102101885B (zh) | 2010-09-01 | 2013-06-05 | 南京发士达生物科技有限公司 | 低诱导抑制性t细胞的人白细胞介素ⅱ突变体及其用途 |
| CN105440123B (zh) * | 2011-02-10 | 2020-10-09 | 罗切格利卡特公司 | 突变体白介素-2多肽 |
| WO2013180200A1 (ja) * | 2012-05-30 | 2013-12-05 | 中外製薬株式会社 | 標的組織特異的抗原結合分子 |
| PT3102595T (pt) * | 2014-02-06 | 2019-01-11 | Hoffmann La Roche | Proteínas de fusão de interleucina-2 e suas utilizações |
| EP3402818A1 (en) * | 2016-01-11 | 2018-11-21 | Universität Zürich | Combination therapy comprising a superagonistic antibody against interleukin-2 and a checkpoint blockade agent |
| KR20240115933A (ko) * | 2016-05-04 | 2024-07-26 | 암젠 인크 | T-조절 세포의 증식을 위한 인터류킨-2 뮤테인 |
| JP7148539B2 (ja) * | 2017-04-03 | 2022-10-05 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 免疫抱合体 |
| CA3052532A1 (en) * | 2017-04-05 | 2018-10-11 | F. Hoffmann-La Roche Ag | Bispecific antibodies specifically binding to pd1 and lag3 |
| AU2018273914A1 (en) * | 2017-05-24 | 2019-11-14 | Pandion Operations, Inc. | Targeted immunotolerance |
| AU2018287317B2 (en) * | 2017-06-19 | 2024-06-20 | Medicenna Therapeutics Inc. | Uses and methods for IL-2 superagonists, agonists, and fusions thereof |
-
2020
- 2020-01-06 CN CN202080018011.6A patent/CN113924311A/zh active Pending
- 2020-01-06 JP JP2021538982A patent/JP7594161B2/ja active Active
- 2020-01-06 EP EP20702547.9A patent/EP3908596A1/en active Pending
- 2020-01-06 TW TW109100336A patent/TWI874345B/zh active
- 2020-01-06 US US17/418,458 patent/US20220089667A1/en active Pending
- 2020-01-06 CA CA3125529A patent/CA3125529A1/en active Pending
- 2020-01-06 MX MX2021008147A patent/MX428580B/es unknown
- 2020-01-06 AR ARP200100028A patent/AR117770A1/es unknown
- 2020-01-06 AU AU2020206672A patent/AU2020206672B2/en active Active
- 2020-01-06 KR KR1020217024431A patent/KR20210113265A/ko active Pending
- 2020-01-06 SG SG11202106700WA patent/SG11202106700WA/en unknown
- 2020-01-06 BR BR112021012294-0A patent/BR112021012294A2/pt unknown
- 2020-01-06 WO PCT/US2020/012296 patent/WO2020146221A1/en not_active Ceased
-
2021
- 2021-07-05 IL IL284633A patent/IL284633A/en unknown
- 2021-07-05 CL CL2021001779A patent/CL2021001779A1/es unknown
-
2024
- 2024-10-22 JP JP2024185692A patent/JP2025013911A/ja active Pending
-
2025
- 2025-12-19 AU AU2025283608A patent/AU2025283608A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005086798A2 (en) * | 2004-03-05 | 2005-09-22 | Chiron Corporation | Improved interleukin-2 muteins |
| WO2016164937A2 (en) * | 2015-04-10 | 2016-10-13 | Amgen Inc. | Interleukin-2 muteins for the expansion of t-regulatory cells |
| WO2018170168A1 (en) * | 2017-03-15 | 2018-09-20 | Cue Biopharma, Inc. | Methods for modulating an immune response |
Also Published As
| Publication number | Publication date |
|---|---|
| TWI874345B (zh) | 2025-03-01 |
| WO2020146221A1 (en) | 2020-07-16 |
| MX428580B (es) | 2025-11-13 |
| KR20210113265A (ko) | 2021-09-15 |
| JP7594161B2 (ja) | 2024-12-04 |
| CN113924311A (zh) | 2022-01-11 |
| JP2025013911A (ja) | 2025-01-28 |
| CA3125529A1 (en) | 2020-07-16 |
| MX2021008147A (es) | 2021-08-11 |
| TW202043259A (zh) | 2020-12-01 |
| JP2022516557A (ja) | 2022-02-28 |
| BR112021012294A2 (pt) | 2021-09-08 |
| IL284633A (en) | 2021-08-31 |
| AU2020206672A1 (en) | 2021-07-15 |
| SG11202106700WA (en) | 2021-07-29 |
| AR117770A1 (es) | 2021-08-25 |
| AU2025283608A1 (en) | 2026-01-22 |
| CL2021001779A1 (es) | 2022-03-04 |
| EP3908596A1 (en) | 2021-11-17 |
| US20220089667A1 (en) | 2022-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7594161B2 (ja) | 修飾il-2ポリペプチドを含むポリペプチド及びその使用 | |
| US20230235005A1 (en) | Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof | |
| US12331126B2 (en) | OX40-binding polypeptides and uses thereof | |
| US20250320295A1 (en) | CD8-Binding Polypeptides and Uses Thereof | |
| SG11202111731WA (en) | Clec12a-binding polypeptides and uses thereof | |
| KR20140069172A (ko) | 항cd 134(ox40) 및 이의 용도 | |
| WO2023004305A1 (en) | Cd8-targeted modified il-2 polypeptides and uses thereof | |
| RU2849624C2 (ru) | Полипептиды, содержащие модифицированный полипептид il-2, и их применения | |
| US20250109203A1 (en) | Gamma Delta T-Cell-Targeted Modified IL-2 Polypeptides and Uses Thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |